AVID BIOSERVICES, IN

CDMO
Delayed Quote. Delayed  - 08/07 04:00:00 pm
7.73USD +0.78%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: April 2020 2021
Net sales1 59,780,7
EBITDA1 -7,492,44
Operating profit (EBIT)1 -10,6-4,13
Operating Margin -17,7%-5,12%
Pre-Tax Profit (EBT)1 -10,5-1,04
Net income1 -15,2-8,55
Net margin -25,4%-10,6%
EPS2 -0,27-0,15
Dividend per Share --
Last update 06/30/2020-
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: April 2020 2021
Net Debt --
Net Cash position --
Leverage (Debt / EBITDA) --
Free Cash Flow1 2,02-6,62
ROE (Net Profit / Equities) --
Shareholders' equity1 --
ROA (Net Profit / Asset) --
Assets1 --
Book Value Per Share --
Cash Flow per Share --
Capex1 3,817,10
Capex / Sales 6,39%8,80%
Last update 06/30/202007/01/2020
1 USD in Million
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 437 M $ -
Valuation 2021e 2022e
P/E ratio (Price / EPS) -51,5x 178x
Capitalization / Revenue 5,41x 4,17x
Yield (DPS / Price) - -
Price to book (Price / BVPS) - -
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -5,12% 6,94%
Operating Leverage (Delta EBIT / Delta Sales) 1,73x 9,25x
Net Margin (Net Profit / Revenue) -10,6% 2,41%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) - -
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   8,80% 19,1%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend